ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

KIN Kindred Biosciences Inc

9.25
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Kindred Biosciences Inc NASDAQ:KIN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.25 9.24 9.26 0 01:00:00

Kindred Biosciences to Announce Third Quarter 2017 Financial Results

11/10/2017 2:01pm

PR Newswire (US)


Kindred Biosciences (NASDAQ:KIN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Kindred Biosciences Charts.

SAN FRANCISCO, Oct. 11, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its third quarter 2017 financial results on November 7, 2017 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.

Kindred Biosciences, Inc. Logo

Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 99251467.

The call will also be webcast live at https://edge.media-server.com/m6/p/rbdv2n48

A replay will also be available at that link for 30 days.

About Kindred Biosciences 

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact

Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com 
(650) 701-7904

 

View original content with multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-announce-third-quarter-2017-financial-results-300534224.html

SOURCE Kindred Biosciences, Inc.

Copyright 2017 PR Newswire

1 Year Kindred Biosciences Chart

1 Year Kindred Biosciences Chart

1 Month Kindred Biosciences Chart

1 Month Kindred Biosciences Chart

Your Recent History

Delayed Upgrade Clock